Gilead Sciences Future Growth

Future criteria checks 1/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Gilead Sciences.

Key information

7.0%

Earnings growth rate

7.8%

EPS growth rate

Biotechs earnings growth	42.5%
Revenue growth rate	2.2%
Future return on equity	n/a
Analyst coverage	Good
Last updated	06 Jun 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

XTRA:GIS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	28,067	7,118	10,057	10,385	23
12/31/2024	27,290	6,803	9,819	10,075	26
12/31/2023	26,697	6,224	9,352	9,622	26
3/31/2020	22,716	4,962	8,244	9,003	N/A
12/31/2019	22,449	5,386	8,319	9,144	N/A
9/30/2019	22,365	2,693	8,039	8,909	N/A
6/30/2019	22,357	5,955	7,639	8,476	N/A
3/31/2019	22,320	5,892	6,758	7,707	N/A
12/31/2018	22,127	5,455	7,476	8,400	N/A
9/30/2018	22,281	1,587	7,912	8,808	N/A
6/30/2018	23,197	2,208	8,432	9,290	N/A
3/31/2018	24,690	3,464	10,559	11,243	N/A
12/31/2017	26,107	4,628	11,308	11,898	N/A
9/30/2017	27,478	11,601	12,145	12,684	N/A
6/30/2017	28,466	12,213	13,775	14,383	N/A
3/31/2017	29,101	12,637	15,510	15,842	N/A
12/31/2016	30,390	13,501	N/A	17,047	N/A
9/30/2016	31,576	15,076	N/A	18,382	N/A
6/30/2016	32,371	16,346	N/A	18,085	N/A
3/31/2016	32,839	17,341	N/A	18,758	N/A
12/31/2015	32,639	18,108	N/A	21,250	N/A
9/30/2015	31,447	16,912	N/A	18,476	N/A
6/30/2015	29,194	15,043	N/A	18,424	N/A
3/31/2015	27,485	14,207	N/A	16,951	N/A
12/31/2014	24,890	12,101	N/A	12,818	N/A
9/30/2014	20,696	9,406	N/A	10,524	N/A
6/30/2014	17,437	7,463	N/A	7,233	N/A
3/31/2014	13,669	4,580	N/A	4,001	N/A
12/31/2013	11,202	3,075	N/A	3,105	N/A
9/30/2013	10,585	3,046	N/A	3,084	N/A
6/30/2013	10,229	2,933	N/A	3,076	N/A
3/31/2013	9,867	2,872	N/A	3,414	N/A
12/31/2012	9,702	2,592	N/A	3,195	N/A
9/30/2012	9,315	2,494	N/A	3,467	N/A
6/30/2012	9,010	2,560	N/A	3,619	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GIS's forecast earnings growth (7% per year) is above the savings rate (0.2%).

Earnings vs Market: GIS's earnings (7% per year) are forecast to grow slower than the German market (15.2% per year).

High Growth Earnings: GIS's earnings are forecast to grow, but not significantly.

Revenue vs Market: GIS's revenue (2.2% per year) is forecast to grow slower than the German market (3.5% per year).

High Growth Revenue: GIS's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GIS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

High growth companies in the Pharmaceuticals & Biotech industry.

Gilead Sciences Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

First quarter 2023 earnings released: EPS: US$0.81 (vs US$0.015 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.66 (vs US$4.96 in FY 2021)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Third quarter 2022 earnings released: EPS: US$1.43 (vs US$2.06 in 3Q 2021)

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Recent updates

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

First quarter 2023 earnings released: EPS: US$0.81 (vs US$0.015 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 3.7% yield

Gilead Sciences, Inc. Announces Updated Positive Results from Three Cohorts of the Phase 2 Trophy-U-01 Study of Trodelvy®

Full year 2022 earnings released: EPS: US$3.66 (vs US$4.96 in FY 2021)

Gilead Sciences, Inc. Announces U.S. FDA Approves Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc.'s Sunlenca(R) (Lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

Kite's Tecartus Car T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New Data From Post-Hoc Analysis from Phase 3 TROPiCS-02 Study

Gilead Sciences, Inc Announces U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis At the Liver Meeting® 2022

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Third quarter 2022 earnings released: EPS: US$1.43 (vs US$2.06 in 3Q 2021)

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Gilead Sciences, Inc. Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living with HIV with A Range of Comorbidities

Gilead Presents Real-World and Long-Term Data from HIV Research Programs At HIV Glasgow 2022

Gilead Sciences, Inc. to Report Q3, 2022 Results on Oct 27, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Hiv-Positive Consumer Joins Lawsuit Against Gilead Sciences, Inc. over Price Gouging

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of MiroBio Ltd.

Gilead Sciences, Inc. Announces Committee for Medicinal Products for Human Use of European Medicines Agency Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for Treatment of Pediatric Patients with COVID-19

Gilead Sciences, Inc. Announces the Positive Overall Survival Results from the Phase 3 TROPiCS-02 Study Evaluating Trodelvy

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy Regardless of Their HER2 Status

Gilead Sciences, Inc. Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

Gilead Sciences, Inc. Announces Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/Her2- Metastatic Breast Cancer Patients in the Tropics-02 Study

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire MiroBio Ltd from SR One Capital Management, LP, Samsara BioCapital LLC, Oxford Science Enterprises, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and Advent Life Sciences LLP for approximately $410 million.

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$1.21 in 2Q 2021)

Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Third Quarter of 2022, Payable on September 29, 2022

Gilead Sciences, Inc. Announces Executive Changes

Gilead Sciences, Inc. Announces Results Reinforcing Biktarvy

Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Gilead Sciences, Inc.'s Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients with Covid-19

Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

GlaxoSmithKline plc (LSE:GSK) completed the acquisition of Sierra Oncology, Inc. (NasdaqGM:SRRA) from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opinion for People with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepcludex® (Bulevirtide) for the Treatment of Chronic Hepatitis Delta Virus (Hdv) Infection

Gilead Sciences New Data Highlights People Living with Hiv Who Are Virally Suppressed Experience Similar Health-Related Quality of Life as General Population

Upcoming dividend of US$0.73 per share

Final Data from Phase 3 Ascent Study Demonstrates Trodelvy Extends Overall Survival over Chemotherapy in Second-Line Metastatic TNBC

Gilead Sciences, Inc. Announces Positive Results from the Primary Analysis of the Phase 3 TROPiCS-02 Study of Trodelvy®

Gilead Sciences, Inc. Announces Executive Changes

U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

First quarter 2022 earnings released: EPS: US$0.015 (vs US$1.38 in 1Q 2021)

Gilead Sciences Announces Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

Gilead Sciences, Inc. Announces Findings from Two Studies, Which Provide Further Insights on the Use of Veklury® (Remdesivir) for the Treatment of Hospitalized and Non-Hospitalized Patients with COVID-19

Gilead Sciences, Inc. to Report Q1, 2022 Results on Apr 28, 2022

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Gilead Sciences, Inc.'s MDS and AML Magrolimab Studies

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Gilead Sciences, Inc's MDS and AML Magrolimab Studies

The Maryknoll Sisters of St. Dominic, Inc Urges Shareholders of Gilead Sciences Inc to Support Its Shareholders Proposal

Kite, a Gilead Company Announces Yescarta Receives U.S. Food and Drug Administration Approval as First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New One-Year Results from the Ongoing Phase 2/3 CAPELLA Trial Evaluating Lenacapavir

Gilead Sciences, Inc. Announces Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

Gilead Sciences, Inc. Announces Veklury (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

GlaxoSmithKline plc Announces Settlement between ViiV Healthcare and Gilead Sciences, Inc

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Gilead Sciences, Inc. Reaches Settlement with ViiV Healthcare Company, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi & Co., Ltd. and GlaxoSmithKline Mercury Limited